Ozempic and the Quiet Drinker: What I See in Executive Cases

He had been on tirzepatide for nine months when his wife called me. He had lost the weight. He was still drinking the way he had been drinking when she first registered the pattern was off. She had read that the medication was supposed to quiet the cravings. It had not quieted his, and she wanted to know what to do with that information.

This is the conversation I am having more often lately. Not because principals are coming to me about a GLP-1. They come to me about a drinking pattern, usually through a spouse, a family office advisor, or a private physician who has run out of leverage. The question about the medication arrives second, often as an aside, often shaped by what the household has read in the press. The press version has decided that GLP-1s are the next thing to fix the drinking. The clinical reality I see is more uneven than that, and it is worth being precise about both before the question gets answered too quickly.

What the 2026 Evidence Actually Shows, and Where the Gap Sits

The signal that GLP-1 medications might affect alcohol consumption was anecdotal long before it was studied. Patients on semaglutide and tirzepatide started reporting, unprompted, that cravings for alcohol had quieted. The first controlled trials caught up to the anecdote in 2025. The clearer one published in 2026.

The Lancet trial published in early 2026 enrolled 108 adults with alcohol use disorder and comorbid obesity. They received either weekly semaglutide or placebo for 26 weeks, alongside standard cognitive behavioral therapy. The semaglutide group reduced their heavy drinking days by 41.1 percent, 13.7 percentage points greater than the placebo group. The number needed to treat came out at 4.3, compared with 7 or higher for the medications already approved for alcohol use disorder.

That is a real signal. It is also a narrow one, and the gap between the trial population and the principal in front of me matters. The trial enrolled patients with both alcohol use disorder and obesity, not with alcohol use disorder alone, and the medication was paired with cognitive behavioral therapy, not given as a standalone intervention. GLP-1s are not approved for alcohol use disorder. The principal who is on Ozempic or Mounjaro for the metabolic picture and is hoping the drinking will quietly resolve in the background is borrowing optimism from a study that did not test what he is asking the medication to do. Sometimes the pull does quiet. The husband whose wife called me is the case where it did not.

Why This Question Is Landing With My Cohort

The executive cohort I work with has a specific profile that makes this question land with weight. A substantial share of these principals are already on semaglutide or tirzepatide, prescribed by their private physician for reasons that have nothing to do with alcohol. The drinking, in many cases, is the part they had not yet brought into a clinical conversation, and possibly had not yet brought into honest conversation with anyone. The pattern I described in the executive blind spot is exactly the population that ends up on a GLP-1 for unrelated reasons and then asks, often hopefully, whether the medication is also handling something else.

It is also the population most exposed to the press version of this story, because they read the financial press and the wellness press in roughly equal measure, and both have been running the same narrative for the better part of a year.

Where I Slow the Conversation Down

A medication that quiets alcohol cravings does not, on its own, address what the drinking was doing. In the executive cohort, the drinking is rarely about the alcohol. It is about the nervous system regulation, the transition between the work day and whatever comes after it, the social currency of the dinner and the deal, the management of a stress load that the principal has organized his life around producing. The GLP-1 may quiet the craving. It does not replace the function the drinking was serving. The principals who do well are the ones who use that quieter window to do the structural and behavioral work that the active craving had previously made very difficult to even attempt. The principals who do less well are the ones who treat the medication as the answer and leave the surrounding architecture untouched.

There is also the medical interaction to be precise about. Combining alcohol with GLP-1 medications can amplify gastrointestinal side effects, increase the risk of hypoglycemia in patients on other glucose-lowering therapies, and in rare cases compound pancreatitis risk. The principal who interprets a quieted craving as permission to drink the way he used to is misreading the situation in a way that has medical consequences. This is the kind of detail that gets lost in the dinner-table version of the story, and it is one of the reasons I want the private physician fully looped in on what the drinking pattern actually looks like.

I am also watching for what happens when these patients eventually come off the medication. The clinical question that has not yet been answered at a population level is whether the drinking pattern stays interrupted or reasserts itself once the pharmacological signal is withdrawn. My working assumption, which is consistent with how I think about the broader role of medication in dependency, is that the medication can buy a window during which the real work needs to happen. The medication is not the work. The medication is, at best, the conditions under which the work becomes possible.

What This Changes in My Coordination Function

When a principal in my practice is already on a GLP-1, the coordination conversation with the private physician has a different shape than it used to. The physician needs to know that the drinking pattern exists and how it has or has not changed, because that information is relevant to the metabolic picture they are managing and to the medication titration schedule they are designing. The principal and the household need to understand that whatever the medication is doing or not doing in the background, the structural work is still the work. My role is to coordinate that picture, not to take a position on whether the medication should be there.

That structural work is the same work I describe in why willpower alone fails. The sleep architecture. The transition rituals. The environmental conditions around the drinking. The social calendar. The honest accounting of what the alcohol was actually doing inside the principal's life that he had not previously named. The medication, when it helps, is a useful tailwind. The work is still the work.

The wife I described at the start of this post ended that first call with a different question than the one she had walked in with. Not whether the medication was supposed to quiet her husband's drinking. What the household and his physician should be doing with the fact that it had not. That is the right question, and it is the conversation I expect to be having more often as the press version of this story keeps spreading faster than the clinical reality of it.